Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations

被引：2
作者：
Marmarelis, Melina E. [1 ]
Langer, Corey J. [1 ]
机构：
[1] Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA
来源：
CLINICAL LUNG CANCER | 2020年 / 21卷 / 05期
关键词：
BRAF; MET; NTRK; RET; ROS1; GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-II; MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; OPEN-LABEL; SINGLE-ARM; CLINICAL CHARACTERISTICS; ROS1; REARRANGEMENTS; ACQUIRED-RESISTANCE; RET REARRANGEMENTS;
D O I：
10.1016/j.cllc.2020.01.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small-cell lung cancer is a major cause of cancer morbidity and mortality worldwide, and these patients have traditionally had a grim prognosis. As our understanding of actionable molecular aberrations that drive oncogenesis has grown, so too has the number of available therapies with improved outcomes in selectively targeted patient populations. This review provides an overview of the clinical response of tumors harboring relatively rare oncogenic drivers to currently approved targeted agents and those in late-stage clinical development. Molecular testing methods available for screening for oncogenic drivers will be discussed. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码：395 / 406
页数：12
相关论文
共 125 条
  • [61] Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
    Lee, S. -H.
    Lee, J. -K.
    Ahn, M. -J.
    Kim, D. -W.
    Sun, J. -M.
    Keam, B.
    Kim, T. M.
    Heo, D. S.
    Ahn, J. S.
    Choi, Y. -L.
    Min, H. -S.
    Jeon, Y. K.
    Park, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (02) : 292 - 297
  • [62] Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
    Lee, Seung Eun
    Lee, Boram
    Hong, Mineui
    Song, Ji-Young
    Jung, Kyungsoo
    Lira, Maruja E.
    Mao, Mao
    Han, Joungho
    Kim, Jhingook
    Choi, Yoon-La
    [J]. MODERN PATHOLOGY, 2015, 28 (04) : 468 - 479
  • [63] Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
    Li, Bob T.
    Shen, Ronglai
    Buonocore, Darren
    Olah, Zachary T.
    Ni, Ai
    Ginsberg, Michelle S.
    Ulaner, Gary A.
    Offin, Michael
    Feldman, Daniel
    Hembrough, Todd
    Cecchi, Fabiola
    Schwartz, Sarit
    Pavlakis, Nick
    Clarke, Stephen
    Won, Helen H.
    Brzostowski, Edyta B.
    Riely, Gregory J.
    Solit, David B.
    Hyman, David M.
    Drilon, Alexander
    Rudin, Charles M.
    Berger, Michael F.
    Baselga, Jose
    Scaltriti, Maurizio
    Arcila, Maria E.
    Kris, Mark G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2532 - +
  • [64] Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
    Lim, Sun Min
    Kim, Hye Ryun
    Lee, Jong-Seok
    Lee, Ki Hyeong
    Lee, Yun-Gyoo
    JooMin, Young
    Cho, Eun Kyung
    Lee, Sung Sook
    Kim, Bong-Seog
    Choi, Moon Young
    Shim, Hyo Sup
    Chung, Jin-Haeng
    La Choi, Yoon
    Lee, Min Jeong
    Kim, Maria
    Kim, Joo-Hang
    Ali, Siraj M.
    Ahn, Myung-Ju
    Cho, Byoung Chul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2613 - +
  • [65] Recent Advances in Targeting ROS1 in Lung Cancer
    Lin, Jessica J.
    Shaw, Alice T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1611 - 1625
  • [66] Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer
    Lin, Jessica J.
    Kennedy, Elizabeth
    Sequist, Lecia V.
    Brastianos, Priscilla K.
    Goodwin, Kelly E.
    Stevens, Sara
    Wanat, Alexandra C.
    Stober, Lisa L.
    Digumarthy, Subba R.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    Gainor, Justin F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 2027 - 2032
  • [67] Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Lindeman, Neal I.
    Cagle, Philip T.
    Beasley, Mary Beth
    Chitale, Dhananjay Arun
    Dacic, Sanja
    Giaccone, Giuseppe
    Jenkins, Robert Brian
    Kwiatkowski, David J.
    Saldivar, Juan-Sebastian
    Squire, Jeremy
    Thunnissen, Erik
    Ladanyi, Marc
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (04) : 415 - 453
  • [68] Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI [10.1016/j.jmoldx.2017.11.004, 10.5858/arpa.2017-0388-CP, 10.1016/j.jtho.2017.12.001]
  • [69] Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
    Lipson, Doron
    Capelletti, Marzia
    Yelensky, Roman
    Otto, Geoff
    Parker, Alex
    Jarosz, Mirna
    Curran, John A.
    Balasubramanian, Sohail
    Bloom, Troy
    Brennan, Kristina W.
    Donahue, Amy
    Downing, Sean R.
    Frampton, Garrett M.
    Garcia, Lazaro
    Juhn, Frank
    Mitchell, Kathy C.
    White, Emily
    White, Jared
    Zwirko, Zac
    Peretz, Tamar
    Nechushtan, Hovav
    Soussan-Gutman, Lior
    Kim, Jhingook
    Sasaki, Hidefumi
    Kim, Hyeong Ryul
    Park, Seung-il
    Ercan, Dalia
    Sheehan, Christine E.
    Ross, Jeffrey S.
    Cronin, Maureen T.
    Jaenne, Pasi A.
    Stephens, Philip J.
    [J]. NATURE MEDICINE, 2012, 18 (03) : 382 - 384
  • [70] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
    Lisberg, A.
    Cummings, A.
    Goldman, J. W.
    Bornazyan, K.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Ledezma, B.
    Mendenhall, M.
    Hunt, J.
    Wolf, B.
    Jones, B.
    Madrigal, J.
    Horton, J.
    Spiegel, M.
    Carroll, J.
    Gukasyan, J.
    Williams, T.
    Sauer, L.
    Wells, C.
    Hardy, A.
    Linares, P.
    Lim, C.
    Ma, L.
    Adame, C.
    Garon, Edward B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
234567891011